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ABSTRACT 
The present study was to evaluate the effect of Terminalia catappa on cognitive functions and cholinesterase (ChE) activity in 
scopolamine-induced amnesia in rats. The extract of Terminalia catappa was administered orally at three doses (100, 200 and 300 
mg/kg) for 7 and 14 consecutive days to the respective groups of rats. Piracetam (120 mg/kg) was used as a standard nootropic 
agent. Learning and memory parameters were evaluated using elevated plus maze (EPM) and passive avoidance. Brain 
cholinesterase activity was evaluated. It was observed that Terminalia catappa at the above- mentioned doses after 7 and 14 days of 
administration in the respective groups significantly reversed scopolamine (1 mg/kg i.p.)- induced amnesia, as evidenced by a 
decrease in the transfer latency in the EPM task and step-down latency in the passive avoidance task. Terminalia catappa reduced 
the brain ChE activity in rats.  
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INTRODUCTION: 
Alzheimer’s disease (AD) is a progressive 
neurodegenerative disorder that's slow in onset but, 
ultimately, results in dementia, uncommon behavior, 
personality change and, ultimately, death. Formation of 
memory is the most complex process and involves 
multiple neural pathways and neurotransmitters. It is 
documented that the cholinergic neural system plays a 
crucial role in learning and memory in humans and 
animals. Despite the great strides that have been made in 
the understanding and management of Alzheimer’s 
disease (AD) and other neurodegenerative diseases, and 
disease related complications are increasing unabated. A 
variety of synthetic drug therapies are available for the 
treatment of Alzheimer but they associated with severe 
side effects and expensive. Therefore, there's an urgent 
need of exploring all the available options to address the 
menace of this disease. Plant medication and herbal 
formulations are frequently thought of to be less toxic 
and free from side effects than synthetic one. In spite of 
the presence of known synthetic medicines in the 
pharmaceutical market, remedies from medicinal plants 
are used with success to treat this disease
1,2
. 
MATERIAL AND METHODS: 
Experimental design  
The experimental design was planned such that the 
effect of Terminalia catappa at doses of 100, 200 and 
300 mg/kg could be evaluated after 7 and 14 days 
against scopolamine-induced amnesia. For this purpose, 
the rats were divided into two sets of eight groups each 
(16 groups). The treatment period for animals of set I 
and set II was 7 and 14 days, respectively. At the end of 
the treatment period, all the animals were subjected to 
scopolamine (1 mg/kg i.p.) 60 min. The cognitive 
paradigms were evaluated 45 min after the scopolamine 
administration using the elevated plus maze (EPM) and 
passive avoidance models. Further, the animals were 
euthanized by cervical decapitation, and the brains were 
isolated to evaluate the anticholinesterase (ChE) activity 
of Terminalia catappa. 




The EPM served as the exteroceptive behavioral model 
(wherein the stimulus existed outside the body) to 
evaluate learning and memory in rats. The plus maze 
apparatus consisted of two open (50 cm × 10 cm × 40 
cm) and two enclosed arms (50 cm × 10 cm × 40 cm), 
with an open roof, arranged such that the two open arms 
were opposite each other. The maze was elevated to a 
height of 50 cm from the ground to measure the anxiety 
index in rats. 
Joshi et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2017; 7(7):197-199                      
ISSN: 2250-1177                                                                             [198]                                                                             CODEN (USA): JDDTAO 
Passive shock avoidance paradigm  
Passive avoidance, based on negative reinforcement, 
was recorded to examine the long-term memory. The 
apparatus consisted of a box (27 cm × 27 cm × 27 cm) 
having three walls of wood and one wall of Plexiglas, 
featuring a grid floor (made up of 3 mm stainless-steel 
rods set 8 mm apart), with a wooden platform (10 cm × 
7 cm × 1.7 cm) in the center of the grid floor. The box 
was illuminated with a 15 W bulb during the 
experimental period. Electric shock was delivered to the 
grid floor. The rats were initially trained and the step-
down latency (SDL) was recorded. SDL is defined as the 
time taken by the rat to step down and place all four 
paws on the grid floor. Rats showing SDL in the range 
of 2-15 s during the training session were taken for the 
acquisition and the retention tasks. The acquisition task 
was carried out 90 min after the training session.  
Biochemical Estimations 
Estimation of ACh Levels in the Brain by 
Quantifying ChE Inhibition 
After assessing the learning and memory paradigms in 
scopolamine- induced amnesia, rats from each group 
were euthanized by cervical decapitation. The whole 
brain was immediately removed and chilled in ice-cold 
phosphate buffer. After washing in ice-cold phosphate 
buffer, the brains were homogenized in 5 ml of 
phosphate buffer in a glass TEFLON homogenizer. The 
brain homogenate was then evaluated for enzyme 
activity using Augustinsson’s method of analysis.  
RESULTS AND DISCUSSION: 
Exteroceptive behavioral models: EPM: The effect of 
the vehicle, scopolamine control, Terminalia catappa 
(100, 200 and 300 mg/kg) and piracetam (120 mg/kg) 
were evaluated at the end of days 7 and 14. The 
scopolamine (1 mg/kg) control group showed a 
significant (P < 0.01) increase in TL values on the 
acquisition as well as on the retention days as compared 
with vehicle control rats, indicating impairment in 
learning and memory. In the AT on day 7 for set I and 
on day 14 for set II, the Terminalia catappa at dose 
levels 100, 200 and 300 mg/kg demonstrated decrease in 
the TL as compared to the scopolamine control group. 
The results obtained were found to be statistically 
significant (P < 0.01). In the RT on day 8 for set I and 
day 15 for set II, the Terminalia catappa at the dose 
levels 100, 200 and 300 mg/kg demonstrated a 
significant (P < 0.01) decrease in the TL as compared to 
the scopolamine control group. Piracetam (120 mg/kg 
p.o.) exhibited marked decrease (P < 0.01) in TL in 
comparison with the scopolamine control group. 
However, Terminalia catappa at the dose levels 200 and 
300 mg/kg showed a decrease in the TL, which is 
comparable to that shown by piracetam (P < 0.01) 
[Table 1]. 
 
Table 1: Effect of the extract of Terminalia catappa on transfer latency (elevated plus maze paradigm) in scopolamine-
induced amnesia in rats 
Treatment Groups 
TL on acquisition day (sec) TL on retention day(sec) 
7 day 14 day 7 day 14 day 
Vehicle control 95.17±14.92 39.83±5.89 55.33±8.77 23.83±4.13 
Scopolamine hydrobromide 143.67±17.2 118.8±11.03 128.33±19.53 118.83±26.13 
Terminalia catappa (100)+ 
Scopolamine (1) 
65.17±7.98 32.17±7.71 40.16±8.16 12.67±2.5 
Terminalia catappa (200)+ 
Scopolamine (1) 
55.5±4.75 17.33±4.73 23.83±3.69 10.17±2.33 
Terminalia catappa (300)+ 
Scopolamine (1) 
30.5±6.67 15.33±3.05 16.83±1.74 3.5±0.34 
Piracetam(120)+ Scopolamine (1) 52.17±9.85 26.67±3.60 34.17±5.21 7.33±2.13 
Values are expressed as mean ± SEM at n=6; one way ANOVA followed by Dunnett’s Test 
Passive shock avoidance paradigm: Scopolamine 
hydrobromide (1 mg/kg i.p.) decreased SDL on the AT 
and RT training, indicating impairment of memory. 
There is a slight increase in SDL after the administration 
of Terminalia catappa (100, 200 and 300 mg/kg p.o.) for 
7 days as compared with the scopolamine control group 
on the AT and RT, indicating improvement in learning 
and memory of rats. However, in the AT, Terminalia 
catappa at the dose levels 100 and 200 mg/kg p.o. 
increased SLD, which is comparable to standard 
piracetam, but failed to exhibit a significant change 
when compared with the scopolamine control after 14 
days of administration. However, Terminalia catappa 
(100, 200 and 300 mg/kg) was found to significantly (P 
< 0.05) decrease the SDL on RT when compared with 
the scopolamine control after 14 days of administration 
[Table 2]. Terminalia catappa 100, 200 and 300 mg/kg) 
after 14 days of administration showed a slight decrease 
in the SDL on acquisition day as compared to the groups 
that received the day 7 administration. However, on the 
retention day, Terminalia catappa (100, 200 and 300 
mg/kg) after 14 days of administration showed a marked 
increase in the SDL as compared to the day 7 
administration groups [Table 2]. 
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Table 2: Effect of the extract of Terminalia catappa on step-down latency (passive avoidance paradigm) in 
scopolamine-induced amnesia in rats 
Treatment Groups 
SDL on acquisition day (sec) SDL on retention day(sec) 
7 day 14 day 7 day 14 day 
Vehicle control 2.67±0.67 1.83±0.47 3.16±0.79  2.16±0.60 
Scopolamine hydrobromide 2.83±0.47 1.17±0.17 1.67±0.49 1.83±0.30 
Terminalia catappa (100)+ 
Scopolamine (1) 
3.67±1.41 3.00±0.58 4.00±0.85 6.00±1.51 
Terminalia catappa (200)+ 
Scopolamine (1) 
2.00±0.51 3.16±0.87 4.17±1.35 6.67±2.35 
Terminalia catappa (300)+ 
Scopolamine (1) 
2.00±0.76 3..33±0.72 5.00±1.49 5.67±1.89 
Piracetam(120)+ Scopolamine (1) 2.5±0.76 3.5±0.72 5.83±1.25 7.00±2.13 
Values are expressed as mean ± SEM at n=6; one way ANOVA followed by Dunnett’s Test 
Table 3: Effect of the extract of Terminalia catappa on AChE Inhibition Activity 
Treatments (mg/kg) AChE concentrated 
(μMol/minute/g of tissue) 
Inhibition of AChE 
activity (%) 
Control 6.742±0.18  
Scopolamine hydrobromide 10.39±0.35 35.11 
Terminalia catappa (100)+Scopolamine (1) 5.683±0.28 45.30 
Terminalia catappa (200)+Scopolamine (1) 4.907±0.31 50.12 
Terminalia catappa (300)+Scopolamine (1) 4.967±0.31 52.19 
Piracetam(120)+ Scopolamine hydrobromide(1) 3.968±0.19 61.8 
Values are expressed as mean ± SEM at n=6; one way ANOVA followed by Dunnett’s Test 
 
Estimation of AChE activity in the brain:  
In the standard group, the animals treated with 
piracetam (120 mg/kg p.o.) produced a significant 
reduction of AChE enzyme activity. In the treatment 
group, the animals treated with Terminalia catappa  at 
100, 200 and 300 mg/kg produced a significant 
reduction of AChE enzyme activity and as compared to 
positive control. Percentage inhibition of AChE activity 
of treatment group has shown a significant increase 
when compared to positive control [Table 3]. 
RESULTS AND DISCUSSION: 
The present study suggests that Terminalia catappa 
possesses memory enhancing activity in view of its 
facilitatory effect on the retention of spatial memory in 
scopolamine-induced amnesia. There is a decrease in the 
TL, i.e. rats were able to locate the dark zone 
immediately after exposure to the open arm in the EPM 
paradigm, which is an indicator of cognition 
improvement. In case of the passive avoidance 
paradigm, the SDL is increased on administration of 
Terminalia catappa. This suggests that the animal has 
the retention of memory of the shock once entered in the 
shock-free zone. The long-term administration of the 
Terminalia catappa extract (14-day administration) 
exhibited pronounced effect in the reversal of the 
scopolamine-induced amnesia in case of the passive 
avoidance paradigm as compared to the 7-days 
administration. 
It is well known that cholinergic neuronal systems play 
an important role in the cognitive deficits associated 
with AD, ageing and neurodegenerative diseases.(24) In 
our study, Piracetam (120 mg/kg p.o.) and Terminalia 
catappa (100, 200 and 300 mg/kg p.o.) significantly 
lowered this activity. Hence, the memory- enhancing 
effect of the Terminalia catappa can be attributed to its 
anti-ChE activity. Therefore, the memory-improving 
activity of Terminalia catappa may be attributed to the 
anti- AChE, procholinergic, neuroprotective and 
nutritive properties of the Terminalia catappa. Hence, 
Terminalia catappa may be used in delaying the onset 
and reducing the severity of Alzheimer’s disease. 
However, further investigations are warranted to explore 
the possible involvement of other neurotransmitters such 
as glutamate, Gamma aminobutyric acid (GABA) and 
catecholamines, responsible for the memory-improving 
property of Terminalia catappa. 
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